News Search Results
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
occurring in ≥2% of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.
More news about: Johnson & Johnson
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
PADCEV occurred in 73% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were PN (22%), rash (16%), COVID19 (10%), diarrhea (5%), pneumonitis/ILD (4.8%), fatigue (3.9%), hyperglycemia (3.6%), increased ALT (3%) and pruritus (2.5%). Adverse reactions leading
More news about: Astellas Pharma Inc.
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
was generally consistent with its established profile in severe asthma.6 The most frequently reported adverse events in the trial were COVID-19, nasopharyngitis and upper respiratory tract infection.6 Regulatory applications are currently under
More news about: Amgen
Oct 16, 2025, 13:46 ET Microsoft extends AI advancements in Dragon Copilot to nurses and partners to enhance patient care
Nurses' job burnout and its association with work environment, empowerment and psychological stress during COVID‐19 pandemic - PMC
More news about: Microsoft Corp.
Oct 16, 2025, 13:23 ET HOME SALES PROFITS UP IN THIRD QUARTER TO NEAR 50 PERCENT MARGIN
Prior to 2020, home sellers saw profit margins of around 30 percent. As the Covid-19 pandemic induced people in search of more space to leave cities and buy homes, profits doubled to more than 60 percent in mid-2022. The typical seller's
More news about: ATTOM
Oct 16, 2025, 10:46 ET Vermont Becomes a Voice for Children with Autoimmune Brain Disorders
Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). These conditions, triggered by infections such as strep or COVID-19, cause the immune system to attack the brain—leading to the sudden onset of obsessive behaviors, anxiety, tics, and other debilitating symptoms.
More news about: Vermont PANDAS/PANS Network
Oct 16, 2025, 10:15 ET Infection Control Market worth $77.67 billion by 2030 with 6.3% CAGR | MarketsandMarkets™
surface cleaners, sanitizers, and germ-protection solutions for both consumer and professional settings. During public health crises, such as the COVID-19 pandemic, Reckitt has stepped up production, supply, and donations of disinfectant and sanitization products to help reduce the spread of infection.
More news about: MarketsandMarkets
Oct 16, 2025, 09:15 ET Deterioration of consumer outlook and spending intentions eases, but no all-clear signal as pressures persist--Bain/Dynata Consumer Health Indexes
below $50,000 per year), the CHI outlook score fell for four prior months in a row, dropping to 94.7 – a level not seen since early 2021, during the COVID-19 pandemic. Spending intentions among the lower-income group also fell, with the CHI gauge of these dropping 1.8 points, to 97.2 in September.
More news about: Bain & Company
Oct 16, 2025, 09:00 ET Nanopath Expands Leadership Team to Drive Next Phase of Scientific and Commercial Growth
improving platform sensitivity more than 1,000-fold. Previously, Dr. Black led the development of the first FDA-authorized at-home molecular test for COVID-19 at Lucira Health, guiding it from feasibility through commercialization. Dr. Black holds a Ph.D. in Chemical Engineering from the University of California,
More news about: Nanopath
Oct 16, 2025, 08:36 ET Workflow Services Launches ECAPS Watch Podcast and Whitepaper to Track Progress of Legislation Pivotal to Pharmacy Industry
Medicare Part B. Once passed, it will enable pharmacists to receive direct reimbursement for test-to-treat clinical services (such as influenza, COVID-19, streptococcal pharyngitis, RSV). By granting pharmacists provider status in Medicare, the bill opens a pathway to large-scale reimbursement, paving
More news about: Workflow Services
Oct 16, 2025, 08:32 ET Not One Refund: Tour Operator's Radical Transparency During COVID Just Won Magellan Gold for Service
TAMPA, Fla., Oct. 16, 2025 /PRNewswire/ -- When COVID-19 shut down travel in March 2020, the playbook was clear: go silent, minimize communication, prepare for refund battles.
More news about: Culture Discovery Vacations
Oct 16, 2025, 07:30 ET BTQ Technologies Demonstrates Quantum-Safe Bitcoin Using NIST Standardized Post-Quantum Cryptography, Protecting $2+ Trillion Market at Risk
conditions in the financial markets; changes in laws (including regulations respecting blockchains); risks related to the direct and indirect impact of COVID-19 including, but not limited to, its impact on general economic conditions, the ability to obtain financing as required, and causing potential delays
More news about: BTQ Technologies Corp.
Oct 15, 2025, 16:00 ET United Airlines Continues to Win Brand-Loyal Customers as Q3 Profit and Q4 Outlook Both Exceed Wall Street Expectations
Excluding years impacted by the COVID-19 pandemic – 2020 and 2021.
More news about: United Airlines
Oct 15, 2025, 13:58 ET NABR komentuje decyzję IUCN
[3] Zob. Albrecht, L., E. Bishop, B. Jay, B. Lafloux, M. Minoves, C. Passaes (2021). COVID-19 Research: Lessons from Non-Human Primate Models (2021) [Badania nad COVID-19: Wnioski płynące z modeli naczelnych innych niż ludzie (2021) doi: 10.3390/vaccines9080886 (dostępne
More news about: National Association for Biomedical Research
Oct 15, 2025, 13:32 ET Stanovisko NABR k rozhodnutí IUCN
3 Viz Albrecht, L., E. Bishop, B. Jay, B. Lafloux, M. Minoves, C. Passaes (2021). COVID-19 Research: Lessons from Non-Human Primate Models (Výzum COVID-19: poznatky z modelů nehumánních primátů) (2021) doi: 10.3390/vaccines9080886 (dostupné na
More news about: National Association for Biomedical Research
Oct 15, 2025, 13:23 ET Comentario de NABR sobre la determinación de la UICN
avances en medicina regenerativa, inmunología, cáncer, desarrollo de vacunas y farmacología, así como para el desarrollo de la vacuna contra la COVID-19. 3 Los Institutos Nacionales de Salud (NIH) publicaron recientemente una revisión que confirma la importancia de los monos «LTM» en la realización
More news about: National Association for Biomedical Research
Oct 15, 2025, 11:30 ET NABR 評論 IUCN 的決定
作出這決定所採用的科學過程，缺乏充足趨勢數據，並歪曲現有數據。」 由於「LTM」猴子的生理和基因與人類相似，因此廣受世界各地生物醫學研究使用。20 種最常用處方藥中，便有 5 種是在「長尾獼猴」的協助下，完成研發。再生醫學、免疫學、癌症、疫苗開發和藥理學的進步，以及 COVID-19 疫苗的研發中，「LTM」猴子的研究參與是至關重要的。3美國國家衛生院 (NIH) 最近發佈一篇評論，證實「LTM」猴子在生物醫學研究中的重要性。 NABR
More news about: National Association for Biomedical Research
Oct 15, 2025, 11:08 ET Komentar NABR Tentang Penetapan IUCN
dipublikasikan). 3 Lihat Albrecht, L., E. Bishop, B. Jay, B. Lafloux, M. Minoves, C. Passaes (2021). COVID-19 Research: Lessons from Non-Human Primate Models (2021) doi: 10.3390/vaccines9080886 (tersedia di
More news about: National Association for Biomedical Research
Oct 15, 2025, 11:05 ET Komentár NABR k rozhodnutiu IUCN
3 Pozri Albrecht, L., E. Bishop, B. Jay, B. Lafloux, M. Minoves, C. Passaes (2021). COVID-19 Research: Lessons from Non-Human Primate Models (Výskum COVID-19: lekcie z modelov neľudských primátov) (2021) doi: 10.3390/vaccines9080886 (k dispozícii na
More news about: National Association for Biomedical Research
Oct 15, 2025, 10:40 ET The Pilates & Yoga Studios Market to Reach $120.88 Billion by 2025 in the short term and $520.61 Billion by 2035 Globally, at 14.3% CAGR: Allied Market Research
attract and keep customers. Attendance and revenue at the studio are further impacted by economic downturns and unanticipated disruptions like the COVID-19 pandemic. Studios can use flexible pricing structures to address these challenges by providing virtual sessions, class packages,
More news about: Allied Market Research
Oct 15, 2025, 10:03 ET Комментарий NABR к решению МСОП
значение для достижений в области регенеративной медицины, иммунологии, рака, разработки вакцин и фармакологии, а также при разработке вакцины от COVID-19. 3 Национальные институты здравоохранения (NIH) недавно опубликовали обзор, подтверждающий важность длиннохвостых макак в проведении
More news about: National Association for Biomedical Research
Oct 15, 2025, 10:01 ET NABR-Kommentar zur IUCN-Bestimmung
angenommen). 3 Siehe Albrecht, L., E. Bishop, B. Jay, B. Lafloux, M. Minoves, C. Passaes (2021). COVID-19 Forschung: Lehren aus nicht-menschlichen Primatenmodellen, „Lessons from Non-Human Primate Models" (2021) doi: 10.3390/vaccines9080886 (available
More news about: National Association for Biomedical Research
Oct 15, 2025, 10:00 ET Commentaire de la NABR sur la détermination de statut de l'UICN
3 Consulter Albrecht, L., E. Bishop, B. Jay, B. Lafloux, M. Minoves, C. Passaes (2021). COVID-19 Research: Lessons from Non-Human Primate Models (2021) doi: 10.3390/vaccins9080886 (disponible sur
More news about: National Association for Biomedical Research
Oct 15, 2025, 08:01 ET Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond
More news about: Lucid Diagnostics
Oct 15, 2025, 08:00 ET SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia
Sarbecoviruses, a subgenus of coronaviruses, include SARS-CoV-2 (COVID-19), the original SARS virus, and related variants. GBP511 is designed to provide broad protection across the sarbecovirus family, moving beyond the strain-specific approach of existing COVID-19 vaccines. The trial will enroll
More news about: SK bioscience